Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

SMShirley S. MoADAmy E. DeZernEFEphraim J. Fuchs

Discussion

Loading...

Member takes

Overview

Analysis shows improved survival in triple-mutated AML patients treated with FLT3 inhibitors, indicating favorable outcomes using modern treatment approaches.

Key Points

  • Patients with triple-mutated AML experience significantly better overall survival compared to non-mutated counterparts.
  • The survival analysis shows a 2-year overall survival of 82% in triple-mutated AML patients versus 50% in non-mutated.
  • Assessment using survival analysis revealed that modern treatment approaches enhance the prognosis of AML.
  • Positive implications for treatment decisions emerge, highlighting the unique responsiveness of triple-mutated AML to FLT3 inhibitors.

Cite This Study

Mo et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d332https://doi.org/10.1182/blood-2025-1710
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: Insights from real-world genomic data2025
  2. 2Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)2025 · 1 citations
  3. 3Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study2025
  4. 4Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.2025 · 3 citations
  5. 5The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.2025